Meeting
2018 ASCO Annual Meeting
CX-01, an inhibitor of CXCL12/CXCR4 axis and of platelet factor 4 (PF4), with azacitidine (AZA) in patients with hypomethylating agent (HMA) refractory AML and MDS.
Authors
Eric Huselton
Washington University in St. Louis, St. Louis, MO
Eric Huselton , Amanda F. Cashen , Meagan Jacoby , Iskra Pusic , Rizwan Romee , Geoffrey L. Uy , John F. DiPersio , Peter Westervelt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT02995655
Citation
J Clin Oncol 36, 2018 (suppl; abstr 7027)
DOI
10.1200/JCO.2018.36.15_suppl.7027
Abstract #
7027
Poster Bd #
87
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A randomized, double-blind, placebo-controlled study of tamibarotene/azacitidine versus placebo/azacitidine in newly diagnosed adult patients selected for RARA+ HR-MDS (SELECT-MDS-1).
First Author: Amy Elizabeth Dezern
Poster
2018 ASCO Annual Meeting
Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes.
First Author: Chun Yew Fong
First Author: Tapan M. Kadia
Poster
2012 ASCO Annual Meeting
A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents.
First Author: Guillermo Garcia-Manero